275 related articles for article (PubMed ID: 18998128)
1. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
Iero M; Filipazzi P; Castelli C; Belli F; Valdagni R; Parmiani G; Patuzzo R; Santinami M; Rivoltini L
Cancer Immunol Immunother; 2009 Jul; 58(7):1159-67. PubMed ID: 18998128
[TBL] [Abstract][Full Text] [Related]
2. Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.
Iero M; Squarcina P; Romero P; Guillaume P; Scarselli E; Cerino R; Carrabba M; Toutirais O; Parmiani G; Rivoltini L
Cancer Immunol Immunother; 2007 Dec; 56(12):1979-91. PubMed ID: 17564703
[TBL] [Abstract][Full Text] [Related]
3. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
4. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope.
Baratin M; Kayibanda M; Ziol M; Romieu R; Briand JP; Guiller JG; Viguier M
J Pept Sci; 2002 Jul; 8(7):327-34. PubMed ID: 12148782
[TBL] [Abstract][Full Text] [Related]
5. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients.
Knights AJ; Nuber N; Thomson CW; de la Rosa O; Jäger E; Tiercy JM; van den Broek M; Pascolo S; Knuth A; Zippelius A
Cancer Immunol Immunother; 2009 Mar; 58(3):325-38. PubMed ID: 18663444
[TBL] [Abstract][Full Text] [Related]
6. Circumventing T-cell tolerance to tumour antigens.
Kessels HW; de Visser KE; Kruisbeek AM; Schumacher TN
Biologicals; 2001; 29(3-4):277-83. PubMed ID: 11851328
[TBL] [Abstract][Full Text] [Related]
7. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic potential of whole tumour cells.
Ward S; Casey D; Labarthe MC; Whelan M; Dalgleish A; Pandha H; Todryk S
Cancer Immunol Immunother; 2002 Sep; 51(7):351-7. PubMed ID: 12192534
[TBL] [Abstract][Full Text] [Related]
9. Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine.
Couty JP; Crain AM; Gerbaud S; Labasque M; Marchiol C; Fradelizi D; Boudaly S; Guettier C; Vignuzzi M; van der Werf S; Escriou N; Viguier M
Cancer Immunol Immunother; 2008 Aug; 57(8):1161-71. PubMed ID: 18256833
[TBL] [Abstract][Full Text] [Related]
10. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
[TBL] [Abstract][Full Text] [Related]
11. Rational peptide-based tumour vaccine development and T cell monitoring.
Scheibenbogen C; Letsch A; Schmittel A; Asemissen AM; Thiel E; Keilholz U
Semin Cancer Biol; 2003 Dec; 13(6):423-9. PubMed ID: 15001161
[TBL] [Abstract][Full Text] [Related]
12. Generation of tumor-specific T-cell therapies.
Morris E; Hart D; Gao L; Tsallios A; Xue SA; Stauss H
Blood Rev; 2006 Mar; 20(2):61-9. PubMed ID: 15978709
[TBL] [Abstract][Full Text] [Related]
13. Influence of p53 on anti-tumor immunity (review).
Bueter M; Gasser M; Lebedeva T; Benichou G; Waaga-Gasser AM
Int J Oncol; 2006 Feb; 28(2):519-25. PubMed ID: 16391808
[TBL] [Abstract][Full Text] [Related]
14. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
Douat-Casassus C; Marchand-Geneste N; Diez E; Gervois N; Jotereau F; Quideau S
J Med Chem; 2007 Apr; 50(7):1598-609. PubMed ID: 17328535
[TBL] [Abstract][Full Text] [Related]
15. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
[TBL] [Abstract][Full Text] [Related]
16. Degenerate recognition and response of human CD4+ Th cell clones: implications for basic and applied immunology.
Nishimura Y; Chen YZ; Uemura Y; Tanaka Y; Tsukamoto H; Kanai T; Yokomizo H; Yun C; Matsuoka T; Irie A; Matsushita S
Mol Immunol; 2004 Feb; 40(14-15):1089-94. PubMed ID: 15036913
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
18. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.
Kyte JA; Trachsel S; Risberg B; thor Straten P; Lislerud K; Gaudernack G
Cancer Immunol Immunother; 2009 Oct; 58(10):1609-26. PubMed ID: 19221745
[TBL] [Abstract][Full Text] [Related]
19. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
van der Burg SH; Bijker MS; Welters MJ; Offringa R; Melief CJ
Adv Drug Deliv Rev; 2006 Oct; 58(8):916-30. PubMed ID: 16979788
[TBL] [Abstract][Full Text] [Related]
20. Development of optimized cryptic peptides for immunotherapy.
Menez-Jamet J; Kosmatopoulos K
IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
